Association of CD40 with rheumatoid arthritis confirmed in a large UK case-control study

Gisela Orozco,1 Steve Eyre,1 Anne Hinks,1 Xiayi Ke,1 Wellcome Trust Case Control Consortium, YEAR consortium, Anthony G Wilson,2 Deborah E Bax,2 Ann W Morgan,3 Paul Emery,3 Sophia Steer,4 Lynne Hocking,5 David M Reid,5 Paul Wordsworth,6 Pille Harrison,6 Wendy Thomson,1 Anne Barton,1 Jane Worthington1

ABSTRACT

Objective A recent meta-analysis of published genome-wide association studies (GWAS) in populations of European descent reported novel associations of markers mapping to the CD40, CCL21 and CDK6 genes with rheumatoid arthritis (RA) susceptibility while a large-scale, case-control association study in a Japanese population identified association with multiple single nucleotide polymorphisms (SNPs) in the CD244 gene. The aim of the current study was to validate these potential RA susceptibility markers in a UK population.

Methods A total of 4 SNPs (rs4810485 in CD40, rs2812378 in CCL21, rs420401 in CDK6 and rs6682654 in CD244) were genotyped in a UK cohort comprising 3962 UK patients with RA and 3531 healthy controls using the Sequenom iPLEX platform. Genotype counts in patients and controls were analysed with the $\chi^2$ test using Stata.

Results Association to the CD40 gene was robustly replicated ($p=2 \times 10^{-4}$, OR 0.86, 95% CI 0.79 to 0.93) and modest evidence was found for association with the CCL21 locus ($p=0.04$, OR 1.08, 95% CI 1.01 to 1.16). However, there was no evidence for association with the CDK6 and CD244 genes in this UK population. Following a meta-analysis including the original data, association to CD40 was confirmed ($p=7.8 \times 10^{-8}$, OR 0.87 (95% CI 0.83 to 0.92)).

Conclusion In this large UK cohort, strong association of the CD40 gene with susceptibility to RA was found, and weaker evidence for association with RA in the CCL21 locus.

INTRODUCTION

Genome-wide association studies (GWAS) have led to a breakthrough in the search for complex disease susceptibility markers.1 Specifically for rheumatoid arthritis (RA), these studies have detected a number of new susceptibility loci, including the 6q21,2-4 TRAF1/C5,5-9 PRKCCQ, KIF5A and IL2RB genetic regions.10 Recently, a meta-analysis of the Wellcome Trust Case Control Consortium (WTCCC) GWAS and a US GWAS confirmed association to PRKCCQ, KIF5A and MMEL and identified additional RA-associated markers mapping to the CD40, CCL21 and CDK6 loci,11 that have yet to be confirmed in an independent UK population. In addition, a recent case-control association study in a Japanese population identified two functional variants mapping to the CD244 gene, rs3766379 and rs6682654, that were associated with RA, again yet to be tested for association in a UK population.12

These studies therefore add to the recent explosion of the number of loci reported to be associated with RA susceptibility. In order for these loci to be confirmed as risk factors for RA, well powered validation studies are required to support these initial findings.

The aims of this study were, therefore, first to validate the additional RA markers derived from the recent meta-analysis (CD40, CCL21 and CDK6) in an independent UK population and, second, to investigate a functional CD244 variant reported to be associated with RA in the Japanese study.10

METHODS

Patients with RA (n=3962) were recruited from six centres (Manchester, Sheffield, Leeds, Aberdeen, Oxford and London) across the UK. All patients were Caucasian of North European ancestry and all fulfilled the 1987 American College of Rheumatology classification criteria modified for genetic studies.13 14 Clinical and demographic characteristics of the cohort are detailed in supplementary table 1. Briefly, 71.8% participants were women, 72.1% were rheumatoid factor positive and 67.9% carried anti-citrullinated protein antibodies (ACPA) as recognised by the anti-cyclic citrullinated protein (CCP) antibody test. This cohort is therefore representative of a hospital-based series of patients with RA. A autoantibody status data was available for 3723 and 2281 patients for rheumatoid factor (RF) and anti-CCP, respectively. Healthy controls (n=3531) were recruited from five of the six centres (patients only recruited from London). All participants were recruited after providing informed consent and the study was approved by the North West Research Ethics Committee (MREC 99/8/84).

Genotyping was performed using the Sequenom iPLEX platform (http://www.sequenom.com) according to the manufacturer’s instructions. All genotyping was performed at the arc Epidemiology Unit, Manchester. Only samples and single nucleotide polymorphisms (SNPs) exceeding a 90% success rate were used in the analysis.

Genotype counts in patients and controls were analysed using Stata software (Stata, College Station, Texas, USA) with the $\chi^2$ test. For the meta-analysis, the Breslow-Day test for homogeneity and the Cochran Mantel–Haenszel test were performed using Stata. For all the tests performed, p values <0.0125 were considered statistically significant, after applying Bonferroni correction for four comparisons.
Power calculations were performed using the Quanto V.0.5 software (Department of Preventive Medicine University of Southern California, California, USA), considering minor allele frequencies and ORs similar to those found in previous studies.\(^4\) \(^3\) \(^1\) \(^2\) \(^11\) \(^12\) at the 5% significance level.

**RESULTS**

We selected four polymorphisms previously reported as RA susceptibility markers for testing in the current study:

1. rs4810485, located in the second intron of the CD40 gene;
2. rs2812378, mapping to the 5′ untranslated region of CCL21;
3. rs42041, positioned in a CDK6 intron;\(^11\)
4. rs6682654, located in CD244, which is an almost perfect proxy of the functional RA marker for the Japanese population within this gene, rs5766379 (\(D′=1, r^2=0.97\)).\(^12\)

Genotype frequencies conformed to Hardy–Weinberg expectations in patients and controls for all the polymorphisms under study. The estimated power of the study was 86% for rs4810485, 77% for rs2812378, 60% for rs42041 and 99% for rs6682654.

Table 1 shows the results of this validation study. Allele frequencies were similar to those previously described in a US population for the CD40, CCL21 and CDK6 markers.\(^11\) We found that the minor T allele of CD40 rs4810485 was significantly increased in healthy controls compared to patients with RA (p=2×10\(^{-4}\), OR 0.86, 95% CI 0.79 to 0.93). This is in accordance with the previous study by Raychaudhuri et al.\(^11\)

When we analysed CCL21 rs2812378, we observed a higher frequency of the minor C allele in patients with RA as previously described,\(^11\) although this skewing seemed to have a more modest effect in our population (p=0.04, OR 1.08, 95% CI 1.01 to 1.16). With regard to CDK6 rs42041, no evidence of association with RA was found in our UK population (table 1).

Additionally, we examined the functional CD244 variant rs6682654, which was previously shown to be associated with RA in a Japanese population.\(^12\) Linkage disequilibrium (LD) between this SNP and the other marker within CD244, rs5766379, also reported to be associated with RA in the Japanese study, is higher in the Caucasian population (\(r^2=0.97, D′=1\)) than in the Japanese population (\(r^2=0.87, D′=1\)).\(^15\) When we compared the distribution of allele and genotype frequencies of rs6682654 between patients and controls, we did not find statistically significant differences (table 1). Allele frequencies of the reference G allele were lower in the UK population than in the previously described Japanese population (0.43 and 0.44 in patients and controls, respectively, for the UK population vs 0.66 and 0.59 in patients and controls, respectively, for the Japanese population), which is in accordance with the data deposited in HapMap (http://www.hapmap.org).

Stratification analysis of the four polymorphisms under study showed that the rs4810485 CD40 SNP was strongly associated with the presence of RF and anti-CCP antibodies (p=8.10×10\(^{-6}\), OR 0.82, 95% CI 0.75 to 0.89 and p=9.52×10\(^{-5}\), OR 0.81, 95% CI 0.73 to 0.90, respectively). CCL21 rs2812378 also showed this trend, but p values for the association with seropositive disease were modest (p=0.02, OR 1.10, 95% CI 1.01 to 1.18 and p=0.03, OR 1.10, 95% CI 1.01 to 1.21, for RF and anti-CCP RA, respectively) (supplementary table 2).

Meta-analysis of these markers was undertaken, pooling data from the previously published RA GWAs,\(^4\) \(^5\) \(^11\) together with data from a validation cohort from the US\(^11\) and our validation study in a UK cohort. p Values for the Breslow–Day test were 0.31 for rs4810485, 0.81 for rs2812378 and 0.02 for rs42041 (table 2). The meta-analysis revealed strong evidence of association with the CD40 variant and a more modest, but suggestive association with the CCL21 variant. The evidence for association with CDK6 was relatively weak.

The rs6682654 SNP mapping to CD244 and showing evidence for association with RA in a Japanese population\(^12\) was not tested in the meta-analysis by Raychaudhuri et al.\(^11\) In order to investigate whether a weak effect on susceptibility could be detected in a UK population, we performed a meta-analysis of the variant, combining imputed data from the WTCCC dataset with that derived from direct genotyping in the current validation study. Pooled analysis revealed no association with RA in the UK population (p=0.87, OR 1.004, 95% CI 0.95 to 1.06). Joint analysis of the Japanese and UK cohorts was not feasible, due to the high degree of genetic heterogeneity between the populations (p\(^{\text{Breslow–Day}}\)=1.8×10\(^{-6}\)).

**DISCUSSION**

In this large UK cohort, we have found strong association of the rs4810485 CD40 variant with susceptibility to RA, and weaker evidence for association with RA in the CCL21 locus. We found no evidence for association with either the CDK6 locus or the

---

**Table 1** Validation study of novel rheumatoid arthritis (RA) susceptibility markers in a UK population

<table>
<thead>
<tr>
<th>Locus</th>
<th>SNP</th>
<th>Minor/ major allele</th>
<th>MAF RA</th>
<th>MAF controls</th>
<th>Genotype frequency, no (%)</th>
<th>Genotype frequency, no (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>RA</td>
<td>Controls</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>11</td>
<td>12</td>
</tr>
<tr>
<td>CD40</td>
<td>rs4810485</td>
<td>T/G</td>
<td>0.23</td>
<td>0.25</td>
<td>165 (4.5)</td>
<td>1334 (36.2)</td>
</tr>
<tr>
<td>CCL21</td>
<td>rs2812378</td>
<td>G/A</td>
<td>0.37</td>
<td>0.35</td>
<td>478 (12.9)</td>
<td>1752 (47.2)</td>
</tr>
<tr>
<td>CDK5</td>
<td>rs42041</td>
<td>G/C</td>
<td>0.25</td>
<td>0.25</td>
<td>228 (6.1)</td>
<td>1402 (37.8)</td>
</tr>
<tr>
<td>CD244</td>
<td>rs6682654</td>
<td>G/A</td>
<td>0.43</td>
<td>0.44</td>
<td>638 (18.1)</td>
<td>1756 (49.8)</td>
</tr>
</tbody>
</table>

MAF, minor allele frequency; SNP, single nucleotide polymorphism.

**Table 2** Meta-analysis of newly identified rheumatoid arthritis (RA) markers in populations of European ancestry

<table>
<thead>
<tr>
<th>Locus</th>
<th>SNP</th>
<th>p Value</th>
<th>OR</th>
<th>p Value</th>
<th>OR (95% CI) for</th>
<th>p Value</th>
<th>OR (95% CI) for</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GWAS meta-analysis(^1)</td>
<td>US validation(^1)</td>
<td>UK validation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD40</td>
<td>rs4810485</td>
<td>2.4×10(^{-7})</td>
<td>0.83</td>
<td>0.002</td>
<td>0.91</td>
<td>2×10(^{-4})</td>
<td>0.86 (0.79 to 0.93)</td>
</tr>
<tr>
<td>CCL21</td>
<td>rs2812378</td>
<td>6.9×10(^{-6})</td>
<td>1.13</td>
<td>9.7×10(^{-4})</td>
<td>1.10</td>
<td>0.04</td>
<td>1.08 (1.01 to 1.16)</td>
</tr>
<tr>
<td>CDK5</td>
<td>rs42041</td>
<td>5.5×10(^{-5})</td>
<td>1.15</td>
<td>0.01</td>
<td>1.08</td>
<td>0.91</td>
<td>0.99 (0.92 to 1.08)</td>
</tr>
</tbody>
</table>

GWAS, genome-wide association studies; SNP, single nucleotide polymorphism.
CD244 variant, previously reported to be associated with RA in Caucasian and Japanese populations, respectively.

The CD40 and CCL21 genes both encode proteins that are involved in immune regulation. CD40 is expressed in a wide variety of immune cells, including B cells, monocytes and dendritic cells, while its ligand, CD154, is expressed by activated CD4 T cells. Binding of CD154 to CD40 provides a critical stimulus for B cell proliferation, immunoglobulin production, isotype switching and upregulation of other costimulatory molecules including B7-related molecules.16 CD40–CD154 interaction appears to have an important role in RA, as expression of CD154 on CD4 T cells in RA promotes increased activation of CD4 T lymphocytes and is associated with active disease. Indeed, blockade of this pathway has been suggested as a potentially useful therapeutic approach in RA and in autoimmune disease in general.16 17 It is interesting to note that the CD40 marker was strongly associated with anti-CCP and RF-positive RA, which suggest that this polymorphism, or other/s in LD with it, could play a role in the regulation of B cell response and the production of autoantibodies. The CCL21 gene encodes a protein that is a homoeostatic lymphoid chemokine instrumental in the recruitment and organisation of T cells and dendritic cells into secondary lymphoid organs, which participate in lymphoid tissue microanatomical organisation in RA.18 Both genes, therefore, are plausible candidates in conferring risk of RA. Although we found statistically significant evidence for association with the CCL21 locus, this would not have remained significant if a correction for multiple testing had been applied and, therefore, confirmation of this locus as an RA susceptibility region will require further investigation in other large data series. It is becoming well established that there exists an ethnic heterogeneity of genetic susceptibility factors in RA, meaning that findings from one ethnic group may not be readily applicable to all. For example, rs2476601 in the PTPN22 gene, which is associated with RA in a European population, but we have found no evidence that the CD40 marker, this is particularly pertinent to the CDK6 rs42041 marker with RA susceptibility. It should be noted that we detected some heterogeneity in the effect sizes between studies (p<0.05), so the pooled OR should be considered with caution and further validation in independent cohorts will be required in order to clarify the role of this variant in RA susceptibility. For the CD40 marker, by contrast, no evidence for association was detected even after pooled analysis of the UK WTCCC and validation datasets, which included approximately 5400 patients with RA and approximately 5800 healthy controls. In this case, genetic heterogeneity would appear to explain the lack of replication as allele frequencies for the rs6682654 SNP are significantly different between the Japanese and UK populations.

In the past year, the first wave of GWAS has improved our understanding of the genetic basis of common, complex diseases, including RA. These studies have made possible the identification of new RA susceptibility loci, such as those mapping to the 6q23, TRAF1/C5, PRKCQ, KIF5A, STAT4 and now CD40. However, these initial GWAS have shown that the effect sizes resulting from associations with common SNPs are modest and, therefore, the remaining RA susceptibility genes may have even smaller effect sizes. Validation studies using large sample sizes and ethnically different populations as well as meta-analysis will be essential to robustly define new potential susceptibility loci. Only then will the investment in fine mapping and functional studies be justified to identify the aetiological variants within the validated loci. In conclusion, we have validated association for CD40 rs4810485 and detected weak evidence for association of CCL21 rs2812378 with RA in a UK population, laying the foundations for further studies of the functional and genetic effects of these variants in conferring risk of disease.

Acknowledgements We acknowledge use of DNA from the British 1958 Birth Cohort collection, funded by the Medical Research Council grant G0000934 and the Wellcome Trust grant 096545/2/02. IT support was provided by Mark Lay, statistical advice from Mark Lunt and technical support by Paul Gilbert, Bhaneta Laid and Stephen G Martin. Nursing support was provided by Janet Grumley, Julie Shotton and Claire Farrar. This work was supported by the Arthritis Research Campaign (grant reference number 17552). We would also like to acknowledge the National Health Service (NHS) Research and Development Support Fund for Guy’s and St Thomas’ and Lewisham NHS Trusts. We acknowledge the arc, Leeds Teaching Hospitals Charitable Trustees and NIHR Leeds Musculoskeletal Biomedical Research Unit for supporting the establishment of the Leeds cohorts. We thank the Manchester Biomedical Research Centre for support.

Competing interests None.

Ethics approval This study was conducted with the approval of the North West Research Ethics Committee (MREC 99/8/84).

Provenance and peer review Not commissioned; externally peer reviewed.

For more information on the WTCCC and YECAR Consortiums, see supplementary material.

REFERENCES


Corrections

The department of one of the authors who co-authored all of the below papers has found that the affiliations were not correct. The correct affiliations for Professor P Emery, for all of the below articles, are: 1Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds; 2NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds, UK.


